Classification and prediction of clinical diagnosis of Alzheimer's disease based on MRI and plasma measures of α-/γ-tocotrienols and γ-tocopherol

Journal of Internal Medicine

Volumn 273, Issue 6, 2013, Pages 602-621

  Mangialasche, F ^a,b   Westman, E ^a,c   Kivipelto, M ^a,d   Muehlboeck, J S ^c   Cecchetti, R ^b   Baglioni, M ^b   Tarducci, R ^e   Gobbi, G ^e   Floridi, P ^e   Soininen, H ^d   Kloszewska I ^f   Tsolaki, M ^g   Vellas, B ^h   Spenger, C ^a   Lovestone, S ^c,i   Wahlund, L O ^a   Simmons, A ^c,i   Mecocci, P ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF PERUGIA   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e Unit of Vascular and Endovascular Surgery   (Italy)

^f MEDICAL UNIVERSITY OF LODZ   (Poland)

^g ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^h UNIVERSITÉ DE TOULOUSE   (France)

ⁱ King s College London   (United Kingdom)

Author keywords

Alzheimer's disease; MRI; Sensitivity; Specificity; Tocopherols; Tocotrienols

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; APOLIPOPROTEIN E; BETA TOCOPHEROL; DELTA TOCOPHEROL; GAMMA TOCOPHEROL; GAMMA TOCOTRIENOL;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NITROSATIVE STRESS; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VITAMIN BLOOD LEVEL;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CHROMANS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; GAMMA-TOCOPHEROL; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; VITAMIN E;

EID: 84877920730     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12037     Document Type: Article

References (77)

1. Albert MS, DeKosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-9.
2. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-9.
3. O'Brien JT. Role of imaging techniques in the diagnosis of dementia. Br J Radiol 2007;80 Spec No 2:S71-7.
4. Ries ML, Carlsson CM, Rowley HA et al. Magnetic resonance imaging characterization of brain structure and function in mild cognitive impairment: a review. J Am Geriatr Soc 2008; 56: 920-34.
5. Westman E, Simmons A, Muehlboeck JS et al. AddNeuroMed and ADNI: similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. Neuroimage 2011; 58: 818-28.
6. Westman E, Simmons A, Zhang Y et al. Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. Neuroimage 2011; 54: 1178-87.
7. Zhang D, Wang Y, Zhou L, Yuan H, Shen D. Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage 2011; 55: 856-67.
8. Lovestone S, Francis P, Kloszewska I et al. AddNeuroMed-the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. Ann N Y Acad Sci 2009; 1180: 36-46.
9. Ray S, Britschgi M, Herbert C et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007; 13: 1359-62.
10. Mangialasche F, Polidori MC, Monastero R et al. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Res Rev 2009; 8: 285-305.
11. Sultana R, Mecocci P, Mangialasche F, Cecchetti R, Baglioni M, Butterfield DA. Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with Alzheimer's disease: insights into the role of oxidative stress in Alzheimer's disease and initial investigations into a potential biomarker for this dementing disorder. J Alzheimers Dis 2011; 24: 77-84.
12. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006; 12: 1005-15.
13. Parks E, Traber MG. Mechanisms of vitamin E regulation: research over the past decade and focus on the future. Antioxid Redox Signal 2000; 2: 405-12.
14. Muller DP, Goss-Sampson MA. Neurochemical, neurophysiological, and neuropathological studies in vitamin E deficiency. Crit Rev Neurobiol 1990; 5: 239-63.
15. Reiter E, Jiang Q, Christen S. Anti-inflammatory properties of alpha- and gamma-tocopherol. Mol Aspects Med 2007; 28: 668-91.
16. Sen CK, Khanna S, Rink C, Roy S. Tocotrienols: the emerging face of natural vitamin E. Vitam Horm 2007; 76: 203-61.
17. Khanna S, Parinandi NL, Kotha SR et al. Nanomolar vitamin E alpha-tocotrienol inhibits glutamate-induced activation of phospholipase A2 and causes neuroprotection. J Neurochem 2010; 112: 1249-60.
18. Khanna S, Roy S, Slivka A et al. Neuroprotective properties of the natural vitamin E alpha-tocotrienol. Stroke; J Cereb Circ 2005; 36: 2258-64.
19. Sen CK, Rink C, Khanna S. Palm oil-derived natural vitamin E alpha-tocotrienol in brain health and disease. J Am Coll Nutr 2010; 29: 314S-23S.
20. Mangialasche F, Xu W, Kivipelto M et al. Tocopherols and tocotrienols plasma levels are associated with cognitive impairment. Neurobiol Aging 2012; 33: 2282-90.
21. Niki E. Tocopherylquinone and tocopherylhydroquinone. Redox Rep 2007; 12: 204-10.
22. Williamson KS, Gabbita SP, Mou S et al. The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain. Nitric Oxide 2002; 6: 221-7.
23. Cui Y, Liu B, Luo S et al. Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors. PLoS ONE 2011; 6: e21896.
24. Thambisetty M, Simmons A, Hye A et al. Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS ONE 2011; 6: e28527.
25. Thambisetty M, Simmons A, Velayudhan L et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 2010; 67: 739-48.
26. Westman E, Muehlboeck JS, Simmons A. Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion. Neuroimage 2012; 62: 229-38.
27. Simmons A, Westman E, Muehlboeck S et al., for the AddNeuroMed consortium. The AddNeuroMed framework for multi-centre MRI assessment of longitudinal changes in Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry 2011; 26: 75-82.
28. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
29. Innovative Medicine Initiative. The AddNeuroMed Study. Scientific aims and objectives of AddNeuroMed. http://www.innomed-addneuromed.com, last accessed on 11 September 2012
30. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566-72.
31. Hachinski VC, Iliff LD, Zilhka E et al. Cerebral blood flow in dementia. Arch Neurol 1975; 32: 632-7.
32. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64.
33. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14.
34. Galasko D, Bennett D, Sano M et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's disease cooperative study. Alzheimer Dis Assoc Disord 1997; 11(Suppl 2): S33-9.
35. Morris JC, Heyman A, Mohs RC et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989; 39: 1159-65.
36. Yesavage J, Sheik J. Geriatric depression scale (GDS): recent evidence and development of a shorter version. Clin Gerontol 1986; 5: 165-73.
37. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington DC: American Psychiatric Association, 1994.
38. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984; 34: 939-44.
39. Petersen RC, Doody R, Kurz A et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-92.
40. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-8.
41. Liu Y, Paajanen T, Westman E et al. APOE epsilon2 allele is associated with larger regional cortical thicknesses and volumes. Dement Geriatr Cogn Disord 2010; 30: 229-37.
42. Jack CR Jr, Bernstein MA, Fox NC et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008; 27: 685-91.
43. Simmons A, Westman E, Muehlboeck S et al. MRI measures of Alzheimer's disease and the AddNeuroMed study. Ann N Y Acad Sci 2009; 1180: 47-55.
44. Segonne F, Dale AM, Busa E et al. A hybrid approach to the skull stripping problem in MRI. Neuroimage 2004; 22: 1060-75.
45. Fischl B, Salat DH, van der Kouwe AJ et al. Sequence-independent segmentation of magnetic resonance images. Neuroimage 2004; 23(Suppl 1): S69-84.
46. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998; 17: 87-97.
47. Fischl B, Liu A, Dale AM. Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med Imaging 2001; 20: 70-80.
48. Segonne F, Pacheco J, Fischl B. Geometrically accurate topology-correction of cortical surfaces using nonseparating loops. IEEE Trans Med Imaging 2007; 26: 518-29.
49. Dale AM, Sereno MI. Improved localizadon of cortical activity by combining EEG and MEG with MRI cortical surface reconstruction: a linear approach. J Cogn Neurosci 1993; 5: 162-76.
50. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA 2000; 97: 11050-5.
51. Fischl B, Sereno MI, Tootell RB, Dale AM. High-resolution intersubject averaging and a coordinate system for the cortical surface. Hum Brain Mapp 1999; 8: 272-84.
52. Desikan RS, Ségonne F, Fischl B et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006; 31: 968-80.
53. Fischl B, van der Kouwe A, Destrieux C et al. Automatically parcellating the human cerebral cortex. Cereb Cortex 2004; 14: 11-22.
54. Traber MG, Jialal I. Measurement of lipid-soluble vitamins-further adjustment needed? Lancet 2000; 355: 2013-4.
55. Wiklund S, Johansson E, Sjostrom L et al. Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models. Anal Chem 2008; 80: 115-22.
56. Trygg J, Wold S. Orthogonal projections to latent structures (O-PLS). J Chemom 2002; 16: 119-28.
57. Eriksson L, Johansson E, Kettaneh-Wold N, Trygg J, Wiksröm C, Wold S. Multi- and Megavariate Data Analysis (Part I -Basics and Principals and Applications). Umeå: Umetrics AB, 2006.
58. Qizilbash S, Chui H, Tariot P, Brodaty H, Kaye J, Erkinjuntti T, 2002. Evindenced-based dementia pratice. Blackwell Publishing, Oxford, 20-23.
59. Hanley J, McNeil B. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-43.
60. McEvoy LK, Holland D, Hagler DJ, Fennema-Notestine C, Brewer JB, Dale AM. Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis. Radiology 2011; 259: 834-43.
61. Marksteiner J, Kemmler G, Weiss EM et al. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2009; 32: 539-40.
62. Rinaldi P, Polidori MC, Metastasio A et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 2003; 24: 915-9.
63. Park HA, Kubicki N, Gnyawali S et al. Natural vitamin E alpha-tocotrienol protects against ischemic stroke by induction of multidrug resistance-associated protein 1. Stroke; J Cereb Circ 2011; 42: 2308-14.
64. Patel V, Rink C, Gordillo GM et al. Oral Tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients. J Nutr 2012; 142: 513-9.
65. Bowman GL, Silbert LC, Howieson D et al. Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging. Neurology 2011; 78: 241-9.
66. Perkins AJ, Hendrie HC, Callahan CM et al. Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. Am J Epidemiol 1999; 150: 37-44.
67. Mangialasche F, Kivipelto M, Mecocci P et al. High plasma levels of vitamin E forms and reduced Alzheimer's disease risk in advanced age. J Alzheimers Dis 2010; 20: 1029-37.
68. Bruno RS, Traber MG. Vitamin E biokinetics, oxidative stress and cigarette smoking. Pathophysiology 2006; 13: 143-9.
69. Vogel S, Contois JH, Tucker KL, Wilson PW, Schaefer EJ, Lammi-Keefe CJ. Plasma retinol and plasma and lipoprotein tocopherol and carotenoid concentrations in healthy elderly participants of the Framingham Heart Study. Am J Clin Nutr 1997; 66: 950-8.
70. White E, Kristal AR, Shikany JM et al. Correlates of serum alpha- and gamma-tocopherol in the women's health initiative. Ann Epidemiol 2001; 11: 136-44.
71. Wright ME, Lawson KA, Weinstein SJ et al. Higher baseline serum concentrations of vitamin E are associated with lower total and cause-specific mortality in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 2006; 84: 1200-7.
72. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
73. Ricciarelli R, Argellati F, Pronzato MA, Domenicotti C. Vitamin E and neurodegenerative diseases. Mol Aspects Med 2007; 28: 591-606.
74. Yaffe K, Weston A, Graff-Radford NR et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 2011; 305: 261-6.
75. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. The New England J Med 2009; 360: 2302-9.
76. Westman E, Cavallin L, Muehlboeck JS et al. Sensitivity and specificity of medial temporal lobe visual ratings and multivariate regional MRI classification in Alzheimer's disease. PLoS ONE 2011; 6: e22506.
77. Farina N, Isaac MG, Clark AR, Rusted J, Tabet N. Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database Syst Rev 2012; CD002854. doi: 10.1002/14651858.CD002854.pub3.